Archives
Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI
2026-06-06
Inflammation-Targeted EPO mRNA Nanoparticles for Ferroptosis Inhibition in Spinal Cord Injury
Study Background and Research Question
Spinal cord injury (SCI) is characterized by an initial mechanical insult followed by a secondary phase marked by persistent neuroinflammation, neuronal loss, and oxidative stress-driven cell death. Among the secondary damage mechanisms, ferroptosis—a form of regulated cell death associated with iron overload and lipid peroxidation—has emerged as a critical contributor to progressive tissue loss and functional decline. While erythropoietin (EPO) is well-known for its hematopoietic effects and has been explored for neuroprotection in SCI, its direct administration is limited by poor lesion targeting and off-target systemic effects. The central research question addressed in the study is whether inflammation-targeted delivery of human erythropoietin mRNA (EPO mRNA) can enhance local EPO production, thereby modulating both inflammation and ferroptosis to improve outcomes after SCI (reference study).Key Innovation from the Reference Study
The core innovation lies in the rational design of a mannose-modified lipid nanoparticle (MLNP) platform engineered for selective delivery of EPO mRNA to CD206-enriched inflammatory macrophages and microglia within the injured spinal cord. This strategy leverages the increased expression of CD206 on macrophages at the lesion site, enabling the nanoparticles to home in on areas of active inflammation. Encapsulation of in vitro transcribed EPO mRNA within these MLNPs protects the mRNA, enhances its stability, and ensures efficient translation to functional EPO protein directly at the injury site. This targeted approach not only increases local therapeutic efficacy but also reduces systemic exposure and associated side effects, overcoming a major barrier in conventional EPO-based therapies (reference study).Methods and Experimental Design Insights
The study implemented a multi-step experimental workflow:- Nanoparticle Engineering: MLNPs were synthesized by incorporating mannose ligands onto the lipid surface, optimizing size, charge, and encapsulation efficiency for EPO mRNA.
- Physicochemical Characterization: The MLNPs exhibited uniform morphology and high mRNA loading capacity, with stability evaluated under physiological conditions.
- Targeting Validation: In vitro assays confirmed selective uptake by CD206+ macrophages, while in vivo biodistribution studies showed preferential accumulation at SCI lesions.
- Therapeutic Assessment: Using a mouse model of SCI, animals received local administration of EPO@MLNPs. Outcomes included neuroinflammation markers, neuronal survival, preservation of serotonergic axons, and motor function recovery.
- Mechanistic Investigations: RNA sequencing and biochemical analyses assessed ferroptosis-related pathways, iron metabolism, and oxidative stress markers following treatment.
Protocol Parameters
- EPO mRNA dosage for encapsulation: Approximately 1 mg/kg body weight, optimized for effective local translation and neuroprotection in murine SCI models.
- MLNP administration: Intrathecal injection at the lesion site within 24 hours post-injury, followed by monitoring for up to 28 days.
- Assessment timeline: Behavioral and histological analysis at 7, 14, and 28 days post-treatment to evaluate neuroinflammation, ferroptosis suppression, and functional outcomes.
- mRNA stability enhancement: Use of modified nucleotides (e.g., pseudouridine) and a poly(A) tail to increase resistance to RNases and prolong half-life, consistent with best practices for mRNA for gene therapy and protein expression studies.
Core Findings and Why They Matter
The inflammation-targeted EPO@MLNPs achieved several key outcomes (reference study):- Localized EPO Expression: Targeted delivery enabled sustained, high-level EPO protein production at the injury site, with minimal systemic exposure.
- Suppression of Neuroinflammation: The treatment significantly lowered pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) and reduced recruitment of inflammatory cells to the lesion.
- Ferroptosis Inhibition: Transcriptomic and biochemical analyses revealed downregulation of iron metabolism genes and lipid peroxidation pathways, with upregulation of anti-ferroptotic regulators such as GPX4.
- Neuroprotection and Functional Recovery: EPO@MLNP-treated animals exhibited reduced neuronal loss, preserved serotonergic axonal integrity, and marked improvements in motor function over untreated controls.